In this week’s video, Dr. Brian G.M. Durie explains how the ARROW study demonstrated efficacy and low toxicity for weekly dosing of carfilzomib.

BOTTOM LINE:​

Ensure your doctor is aware of the ARROW study in order to consider once-weekly dosing of carfilzomib.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org

Previous Post
What are the immediate and long-term side effects of an autologous stem cell transplant (ASCT)?
Next Post
Multiple Myeloma Background, Shared Decision Making, and Smoldering Update

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.